SCHEMBL13675864

SCHEMBL13675864

O=C(/C=C/c1ccc(C(F)(F)F)nc1N1CCOCC1)Nc1ccc2ncsc2c1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.71
NPC1 O15118 3/20 0.46
RAB9A P51151 2/20 0.46
USP30 Q70CQ3 1/20 0.43
RAF1 P04049 1/20 0.41
BRAF P15056 1/20 0.41
IKBKB O14920 1/20 0.41
CHUK O15111 1/20 0.41
MCHR1 Q99705 2/20 0.40
NAMPT P43490 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
CHRM5 P08912 2/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
CLK1 P49759 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
OTUD7B Q6GQQ9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675798 0.91 TRPV1 (0.70) TRPV1NPC1RAB9AUSP30IKBKB
SCHEMBL13675843 0.89 TRPV1 (0.57) TRPV1NPC1RAB9AUSP30MCHR1
SCHEMBL13675846 0.84 TRPV1 (0.52) TRPV1NPC1RAB9AUSP30MCHR1
SCHEMBL3997117 0.83 TRPV1 (1.00) TRPV1NPC1RAB9AKMT2AMEN1
SCHEMBL3997657 0.81 TRPV1 (0.63) TRPV1NPC1RAB9AUSP30MCHR1
SCHEMBL3997649 0.81 TRPV1 (0.63) TRPV1NPC1RAB9AUSP30MCHR1
SCHEMBL13675859 0.81 TRPV1 (0.71) TRPV1NPC1RAF1BRAFMCHR1
SCHEMBL13675800 0.76 TRPV1 (1.00) TRPV1NPC1RAB9AKMT2AMEN1
SCHEMBL3777867 0.76 TRPV1 (0.63) TRPV1KMT2AMEN1POLBMAPT
SCHEMBL3777869 0.76 TRPV1 (0.63) TRPV1KMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 TRPV1 1/4885NPC1 2982/4885RAB9A 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.